Suchergebnisse - "Stagno, Fabio"

PubPharm (204)

1

Oxidative Stress and Chronic Myeloid Leukemia : A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors

enthalten in: Antioxidants (Basel, Switzerland) | 2024

von Allegra, A. | Mirabile, G. | Caserta, S. | +4

2

Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

enthalten in: Journal of clinical medicine | 2024

von Roszkowska, A. | Leanza, R. | Aragona, E. | +7

3

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

enthalten in: Blood | 2024

von Crespiatico, I. | Zaghi, M. | Mastini, C. | +37

CommentIn: Blood. 2024 Apr 4;143(14):1323-1324. - PMID 38573606

4

The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients : 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Malagola, M. | Iurlo, A. | Bucelli, C. | +27

5

The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

enthalten in: Annals of hematology | 2024

von Mulas, O. | Abruzzese, E. | Luciano, L. | +26

6

Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw

enthalten in: International journal of molecular sciences | 2024

von Caserta, S. | Stagno, F. | Gangemi, S. | +1

7

The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

enthalten in: Annals of hematology | 2023

von Mulas, O. | Abruzzese, E. | Luciano, L. | +26

8

Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation : Final analysis of the TFR-PRO study

enthalten in: American journal of hematology | 2023

von Zambrotta, G. | Nicolini, F. | Assouline, S. | +25

9

Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation : final analysis of the TFR-PRO study

enthalten in: American journal of hematology | November 2023

von Zambrotta, G. | Nicolini, F. | Assouline, S. | +25

10

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia : A study from the Registro Italiano LMC and Campus CML

enthalten in: Cancer | 2023

von Tiribelli, M. | Latagliata, R. | Breccia, M. | +38

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]